Supplement, NHP or Drug: Where the Line Sits
Classification follows the claim and the market, not the molecule.

Vegalab is a delivery technology and formulation partner. It does not sell drugs, peptides or research chemicals. This section states the rules that decide what a partner can lawfully make with our platform, and what we will not accept as a project.
The supplement, natural health product and drug page sets out how the same molecule can be a lawful dietary ingredient in one market, a licensed natural health product in another, and an unapproved drug in a third. It covers the US new dietary ingredient notification route, the Canadian natural health product license, EU food supplement and novel food rules, and the point at which a claim rather than a molecule creates a drug. Classification is the first question in any feasibility scope, because it determines the evidence and the label.
The peptide regulatory status page explains why most peptides circulating in the wellness market have no approved human use, how compounding lists and research-chemical labeling work, and why an unapproved status is not a gap to be exploited. The anti-doping page covers the World Anti-Doping Code, including the non-approved substances clause that captures compounds with no regulatory approval anywhere, and the growth factor and secretagogue categories relevant to partners who serve athletes.
The stewardship position is written down so partners do not have to guess. Vegalab does not formulate for unapproved human use, does not supply compounds for resale as research chemicals, does not write dosing protocols, and does not support claims the evidence does not carry. The page lists the categories we turn away and the questions we ask before a feasibility agreement is signed. The same page states what Vegalab does take on: approved-molecule reformulation, licensed supplement and natural health product development, cosmetic and veterinary formats, and preclinical support for qualified sponsors.
Delivery work is regulated by what the finished product claims, not by the carrier. Because a multi-layer particle can be filled into a supplement capsule, a cosmetic base or a licensed medicine, we scope the regulatory pathway before the formulation, so the encapsulation design matches the evidence the partner can actually generate for that market.
Tell us your target market and claim, and we will map the pathway before we formulate.
Classification follows the claim and the market, not the molecule.
Peptides fall into four regulatory buckets: approved medicines, investigational drugs in a sponsored trial, lawful ingredients in a specific market, and compounds with no approved human use anywhere.
If a partner's product will be used by competitive athletes, anti-doping status is a formulation constraint, not a footnote.
Stating the limits in advance saves everyone time.
Last updated: